OncoMatch/Leukemia — Acute Myeloid (AML)/FLT3
Leukemia — Acute Myeloid (AML)FLT3 Clinical Trials
FLT3 mutations — internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations — are the most common recurrent alterations in AML, present in ~30% of patients and associated with high relapse risk. Midostaurin combined with induction chemotherapy is first-line standard for FLT3-mutant AML; gilteritinib is approved for relapsed/refractory disease. Trials investigate second-generation FLT3 inhibitors, triplet combinations with venetoclax, and post-transplant maintenance.
Top recruiting FLT3 Leukemia — Acute Myeloid (AML) trials
Ranked by phase and US site count.
See all trials matched to your profile →A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Oncology Group
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Sunshine Lake Pharma Co., Ltd.
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
University Hospital, Angers
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Hutchmed
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
The First Affiliated Hospital of Soochow University